INOLYSIS Receives ERC PoC Funding to Advance Innovative IBD Therapy

INOLYSIS has been awarded an ERC Proof of Concept Grant to support the development of a novel oral therapy targeting fibroblast-driven inflammation and fibrosis in IBD. This prestigious grant from the European Research Council (ERC) will accelerate the development of INOLYSIS’s lead compound VM-313, an innovative oral therapy that uniquely targets fibroblasts—the key cellular drivers of inflammation and fibrosis in Inflammatory Bowel Disease (IBD). The funding will enable preclinical validation, mechanistic studies, and commercialization planning, advancing a promising therapeutic approach that combines anti-inflammatory and anti-fibrotic activity to address an important unmet medical need.

Read more in the official press release: INOLYSIS ERC PoC Grant Press Release